niclosamide has been researched along with Diabetes Mellitus, Type 2 in 8 studies
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Niclosamide piperazine salt may hold the promise to become an alternative to NEN as a drug lead for the treatment of obesity and T2D." | 7.91 | Niclosamide piperazine prevents high-fat diet-induced obesity and diabetic symptoms in mice. ( Alasadi, A; Guo, J; Huang, Q; Jin, S; Tao, H, 2019) |
| "Niclosamide is an oral antihelminthic drug used to treat parasitic infections in millions of people worldwide." | 4.98 | Niclosamide: Beyond an antihelminthic drug. ( Chen, W; Mook, RA; Premont, RT; Wang, J, 2018) |
| "Niclosamide piperazine salt may hold the promise to become an alternative to NEN as a drug lead for the treatment of obesity and T2D." | 3.91 | Niclosamide piperazine prevents high-fat diet-induced obesity and diabetic symptoms in mice. ( Alasadi, A; Guo, J; Huang, Q; Jin, S; Tao, H, 2019) |
| "Metabolic disorders such as type 2 diabetes, fatty liver disease, hyperlipidemia, and obesity commonly co-occur but clinical treatment options do not effectively target all disorders." | 2.44 | Head-to-head comparison of BAM15, semaglutide, rosiglitazone, NEN, and calorie restriction on metabolic physiology in female db/db mice. ( Alexopoulos, SJ; Beretta, M; Byrne, FL; Cantley, J; Chen, SY; Garcia, CJ; Hoehn, KL; Larance, M; Olzomer, EM; Philp, A; Salamoun, JM; Santos, WL; Shah, DP; Smith, GC; Turner, N, 2024) |
| "Diabetic peripheral neuropathy (DPN), diabetic kidney disease (DKD), and diabetic retinopathy (DR) contribute to significant morbidity and mortality in diabetes patients." | 1.51 | Mitochondrial uncoupling has no effect on microvascular complications in type 2 diabetes. ( Abcouwer, SF; Backus, C; Brosius, FC; Feldman, EL; Hayes, JM; Hinder, LM; Kayampilly, P; Lin, CM; O'Brien, PD; Pennathur, S; Rumora, AE; Sas, KM; Shanmugam, S; Zhang, H, 2019) |
| "Early diabetic kidney disease (DKD) is characterized by renal hypertrophy and albuminuria." | 1.48 | Niclosamide ethanolamine improves kidney injury in db/db mice. ( Ge, N; Han, P; Li, S; Shao, M; Song, G; Sun, H; Wang, W; Yi, T; Yu, X; Zhan, H; Zhang, C, 2018) |
| " Although the pharmacokinetic properties of NIC are appropriate for use as an anthelmintic agent, its low solubility, low bioavailability and low systemic exposure limit its usefulness in treating systemic diseases." | 1.46 | Niclosamide-conjugated polypeptide nanoparticles inhibit Wnt signaling and colon cancer growth. ( Bhattacharyya, J; Chen, W; Chilkoti, A; Li, X; Mook, RA; Premont, RT; Ren, XR; Spasojevic, I; Wang, J, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, SY | 1 |
| Beretta, M | 1 |
| Olzomer, EM | 1 |
| Alexopoulos, SJ | 1 |
| Shah, DP | 1 |
| Byrne, FL | 1 |
| Salamoun, JM | 1 |
| Garcia, CJ | 1 |
| Smith, GC | 3 |
| Larance, M | 1 |
| Philp, A | 1 |
| Turner, N | 2 |
| Santos, WL | 1 |
| Cantley, J | 1 |
| Hoehn, KL | 1 |
| Chen, W | 2 |
| Mook, RA | 2 |
| Premont, RT | 2 |
| Wang, J | 2 |
| Guo, J | 1 |
| Tao, H | 1 |
| Alasadi, A | 1 |
| Huang, Q | 1 |
| Jin, S | 1 |
| Bhattacharyya, J | 1 |
| Ren, XR | 1 |
| Spasojevic, I | 1 |
| Li, X | 1 |
| Chilkoti, A | 1 |
| Han, P | 1 |
| Zhan, H | 1 |
| Shao, M | 1 |
| Wang, W | 1 |
| Song, G | 1 |
| Yu, X | 1 |
| Zhang, C | 1 |
| Ge, N | 1 |
| Yi, T | 1 |
| Li, S | 1 |
| Sun, H | 1 |
| Hinder, LM | 1 |
| Sas, KM | 1 |
| O'Brien, PD | 1 |
| Backus, C | 1 |
| Kayampilly, P | 1 |
| Hayes, JM | 1 |
| Lin, CM | 1 |
| Zhang, H | 1 |
| Shanmugam, S | 1 |
| Rumora, AE | 1 |
| Abcouwer, SF | 1 |
| Brosius, FC | 1 |
| Pennathur, S | 1 |
| Feldman, EL | 1 |
| Chowdhury, MK | 2 |
| Wu, LE | 2 |
| Coleman, JL | 1 |
| Smith, NJ | 1 |
| Morris, MJ | 2 |
| Shepherd, PR | 2 |
| Bentley, NL | 1 |
| Das, A | 1 |
| Richani, D | 1 |
| Bustamante, S | 1 |
| Gilchrist, RB | 1 |
1 review available for niclosamide and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Niclosamide: Beyond an antihelminthic drug.
Topics: Animals; Anthelmintics; Arthritis, Rheumatoid; Diabetes Mellitus, Type 2; Disease Models, Animal; En | 2018 |
7 other studies available for niclosamide and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Head-to-head comparison of BAM15, semaglutide, rosiglitazone, NEN, and calorie restriction on metabolic physiology in female db/db mice.
Topics: Animals; Caloric Restriction; Diabetes Mellitus, Type 2; Ethanolamine; Ethanolamines; Female; Mice; | 2024 |
Niclosamide piperazine prevents high-fat diet-induced obesity and diabetic symptoms in mice.
Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Insulin Resistance; Mice | 2019 |
Niclosamide-conjugated polypeptide nanoparticles inhibit Wnt signaling and colon cancer growth.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Diabetes Mellitus, Type 2; Humans; | 2017 |
Niclosamide ethanolamine improves kidney injury in db/db mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Ethanol | 2018 |
Mitochondrial uncoupling has no effect on microvascular complications in type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopa | 2019 |
Niclosamide blocks glucagon phosphorylation of Ser552 on β-catenin in primary rat hepatocytes via PKA signalling.
Topics: Animals; beta Catenin; Bucladesine; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; | 2016 |
Niclosamide reduces glucagon sensitivity via hepatic PKA inhibition in obese mice: Implications for glucose metabolism improvements in type 2 diabetes.
Topics: Animals; Body Composition; Body Weight; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Typ | 2017 |